Imunon, Inc. (IMNN)
- Previous Close
1.3800 - Open
1.4200 - Bid --
- Ask --
- Day's Range
1.2935 - 1.4800 - 52 Week Range
0.4800 - 2.0000 - Volume
27,585 - Avg. Volume
222,765 - Market Cap (intraday)
13.912M - Beta (5Y Monthly) 2.04
- PE Ratio (TTM)
-- - EPS (TTM)
-2.1600 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
imunon.comRecent News: IMNN
Performance Overview: IMNN
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMNN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMNN
Valuation Measures
Market Cap
13.91M
Enterprise Value
-159.25k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.04
Enterprise Value/Revenue
4.00
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.89%
Return on Equity (ttm)
-91.37%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-19.51M
Diluted EPS (ttm)
-2.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
15.7M
Total Debt/Equity (mrq)
12.14%
Levered Free Cash Flow (ttm)
-12.13M
Research Analysis: IMNN
Company Insights: IMNN
IMNN does not have Company Insights